SCHEMBL3749601

SCHEMBL3749601

FC(F)(F)C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(C(F)(F)F)C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1279924 0.87 MEN1 (0.33) MEN1KMT2ATDP1
SCHEMBL11612420 0.83 MEN1 (0.44) MEN1KMT2ATDP1
SCHEMBL8402370 0.83 MEN1 (0.44) MEN1KMT2ATDP1
SCHEMBL27997087 0.78 MEN1 (0.47) MEN1KMT2ATDP1
SCHEMBL10354566 0.76 MEN1 (0.37) MEN1KMT2ATDP1
SCHEMBL25327648 0.75 MEN1 (0.50) MEN1KMT2ATDP1
SCHEMBL10186548 0.75 MEN1 (0.50) MEN1KMT2ATDP1
SCHEMBL9803044 0.75 MEN1 (0.50) MEN1KMT2ATDP1
SCHEMBL144465 0.75 MEN1 (0.50) MEN1KMT2ATDP1
SCHEMBL1279986 0.75 MEN1 (0.50) MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020065326-A1 Patient oxygenation using stabilized fluorocarbon emulsions WEERS JEFFRY GREG (US) 2002-05-30 US claimed
US-5914352-A Methods for the use of stabilized fluorocarbon emulsions ALLIANCE PHARMACEUTICAL CORP. (US) 1999-06-22 US claimed
US-5628930-A STORAGE STABILITY ALLIANCE PHARMACEUTICAL CORP. (US) 1997-05-13 US claimed
EP-0666736-A1 STABILIZATION OF FLUOROCARBON EMULSIONS. ALLIANCE PHARMA (US) 1995-08-16 EP claimed
WO-1994009625-A2 STABILIZATION OF FLUOROCARBON EMULSIONS ALLIANCE PHARMACEUTICAL CORP. (US) 1994-05-11 WO claimed
US-10590381-B2 Composition for collecting and preserving placental stem cells and methods of using the composition Celularity, Inc. (US) 2020-03-17 US disclosed
US-20170327788-A1 COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION ANTHROGENESIS CORPORATION (US) 2017-11-16 US disclosed
US-9725694-B2 Composition for collecting and preserving placental stem cells and methods of using the composition ANTHROGENESIS CORPORATION (US) 2017-08-08 US disclosed
US-9598669-B2 Composition for collecting placental stem cells and methods of using the composition ANTHROGENESIS CORPORATION (US) 2017-03-21 US disclosed
US-20100291679-A1 COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION ANTHROGENESIS CORPORATION 2010-11-18 US disclosed
EP-1974013-A2 IMPROVED COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION Anthrogenesis Corporation (US) 2008-10-01 EP disclosed
US-20070190042-A1 Composition for collecting and preserving placental stem cells and methods of using the composition Celularity, Inc. 2007-08-16 US disclosed
WO-2007079185-A2 IMPROVED COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION ANTHROGENESIS CORPORATION (US) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070190042-A1 Composition for collecting and preserving placental stem cells and methods of using the composition PGF, ALPP, CPA1 MEN1 3150/4885KMT2A 3422/4885TDP1 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.